Qvanteq AG

Qvanteq develops novel stent technologies to address and overcome the clinically adverse effects of today’s available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.

Qvanteq is ISO 13485 certified. It is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012. Qvanteq was founded in early 2009 and is held by private investors. Its Headquarter is located at the Technopark in Zurich, Switzerland.